GNH USA

Europe — EMA

Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

GNH USA supplies Mydriasert (Phenylephrine Hydrochloride/Tropicamide), a mydriatic agent for pupil dilation in diagnostic eye exams.

Phenylephrine Hydrochloride, Tropicamide

Request sourcing

1
Pack/s

What is Phenylephrine Hydrochloride, Tropicamide?

Phenylephrine Hydrochloride/Tropicamide, the active ingredient in Mydriasert, is a mydriatic agent presented as an ophthalmic solution for ocular (topical) use. It dilates the pupil to facilitate diagnostic and surgical eye procedures. GNH USA supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Phenylephrine Hydrochloride, Tropicamide used for?

Mydriasert, a combination mydriatic agent, is employed to induce pupil dilation for ophthalmic examinations.

Diagnostic ophthalmic procedures: provides sufficient mydriasis to allow detailed fundus evaluation. Retinal examination: enables clear visualization of retinal structures for screening and monitoring. Pre‑operative preparation: creates a stable, dilated pupil before intraocular surgery.

What are the side effects of Phenylephrine Hydrochloride, Tropicamide?

Mydriasert may cause ocular and systemic reactions after administration.

Common Side Effects: - Transient ocular redness or irritation. - Mild headache. - Temporary blurred vision. - Photophobia.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma. - Severe allergic reaction (e.g., rash, swelling). - Systemic hypertension or cardiovascular events. - Prolonged mydriasis lasting several hours. - Significant ocular pain.

What precautions apply to Phenylephrine Hydrochloride, Tropicamide?

Before using Mydriasert, consider the following safety measures.

Assess intraocular pressure: ensure baseline measurement, especially in glaucoma patients. Narrow‑angle glaucoma: avoid or use with extreme caution. Cardiovascular disease: monitor for hypertensive response. Children: limit exposure to reduce systemic absorption. Concurrent mydriatics: avoid combining with other agents that cause pupil dilation. Store at room temperature: keep in original container, protect from light and moisture.

What does Phenylephrine Hydrochloride, Tropicamide interact with?

Mydriasert can interact with other medications; review patient medication lists.

Major Interactions (Avoid): - Systemic α‑adrenergic agonists (e.g., phenylephrine oral): risk of excessive hypertension. - Other anticholinergic ophthalmic agents: may cause excessive mydriasis and cycloplegia. - Monoamine oxidase inhibitors: potential for heightened systemic adrenergic effects.

Moderate Interactions (Monitor Closely): - Topical beta‑blockers: may affect intraocular pressure control. - Systemic antihypertensives: may mask blood pressure changes. - Antihistamine eye drops: could enhance anticholinergic activity.

Frequently asked questions

What is Mydriasert used for?+
Mydriasert is a combination ophthalmic solution used to dilate the pupil (mydriasis) and temporarily paralyze the eye's focusing ability (cycloplegia). It is commonly employed before retinal examinations, diagnostic fundus imaging, and intraocular surgeries to provide a clear view of internal eye structures.
How does phenylephrine hydrochloride/tropicamide work?+
Phenylephrine hydrochloride stimulates α1‑adrenergic receptors in the dilator pupillae muscle, causing it to contract and widen the pupil. Tropicamide blocks muscarinic receptors in the iris sphincter, preventing constriction. Together they produce rapid and sustained pupil dilation and cycloplegia.
What is the usual dose of Mydriasert?+
The specific dosing regimen for Mydriasert is determined by the prescribing eye care professional based on the patient’s age, clinical indication, and response. Typically, one drop is instilled in the conjunctival sac of each eye, but exact frequency and concentration are set by the clinician.
Is Mydriasert safe during pregnancy or breastfeeding?+
Safety data for Mydriasert in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss alternatives when appropriate.
How do I order Mydriasert from GNH USA?+
To request Mydriasert, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.
How does Mydriasert compare with other mydriatic agents?+
Mydriaset combines phenylephrine, an α1‑agonist, with tropicamide, an antimuscarinic, offering both rapid dilation and cycloplegia. Compared with agents like atropine (long‑acting) or cyclopentolate (moderate duration), Mydriaset provides a quicker onset and shorter duration, making it suitable for routine diagnostic procedures.
What are the storage and handling requirements for Mydriasert?+
Mydriasert should be stored at room temperature, below 25 °C, in its original container. Protect the solution from direct sunlight, moisture, and freezing. Keep the vial tightly sealed when not in use to maintain sterility.
How is Mydriasert administered?+
Mydriasert is applied topically to the eye. The prescriber typically instructs the patient to instill one drop into the conjunctival sac of each eye, avoiding contact with the eyelid or lashes. The drop should be administered using a clean fingertip or applicator, and the patient should blink gently to spread the solution.
What are the most serious risks associated with Mydriasert?+
The most serious risks include acute angle‑closure glaucoma, severe allergic reactions such as anaphylaxis, and systemic hypertension or cardiovascular events due to phenylephrine absorption. Patients should be monitored for sudden eye pain, visual changes, or systemic symptoms and seek immediate medical attention if they occur.
Who should not use Mydriasert?+
Mydriasert is contraindicated in individuals with known hypersensitivity to phenylephrine, tropicamide, or any formulation components. It should also be avoided in patients with narrow‑angle or uncontrolled glaucoma, severe cardiovascular disease, or those taking systemic α‑adrenergic agonists without medical supervision.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Phenylephrine Hydrochloride, Tropicamide
Route
Ocular Use
Manufacturer
Laboratoires Thea
Origin
EU

Related products

Mydriasert

Mydriasert

Phenylephrine Hydrochloride, Tropicamide

Laboratoires Thea
EU
Mydriasert

Mydriasert

Phenylephrine Hydrochloride, Tropicamide

Laboratoires Thea
EU
Mydriasert

Mydriasert

Phenylephrine Hydrochloride, Tropicamide

Laboratoires Thea
EU
Mydriasert

Mydriasert

Phenylephrine Hydrochloride, Tropicamide

Laboratoires Thea
EU